[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07734415":3,"trial-entities:NCT07734415":260,"trial-summary:NCT07734415":263},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":29,"primary_purpose":30,"phases":31,"enrollment_info":33,"interventions":36,"primary_outcomes":42,"secondary_outcomes":47,"sex":68,"minimum_age":69,"maximum_age":70,"healthy_volunteers":71,"eligibility_criteria":72,"std_ages":76,"locations":79,"central_contacts":256,"overall_officials":257,"references":258,"see_also_links":259},"NCT07734415","IMG-007-205","Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis","A Long-term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous IMG-007 in Participants of a Previous IMG-007 Moderate-To-Severe Atopic Dermatitis Clinical Trial","ENROLLING_BY_INVITATION","2028-03","2026-07","2026-07-29","2026-06-05","Inmagene LLC","INDUSTRY",true,"The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)",null,[19,20,21],"Atopic Dermatitis","Atopic Dermatitis Eczema","Eczema",[23,19,24,25,21,26,27,28],"IMG-007","Dermatitis, Atopic","Dermatitis","Skin Diseases","Immune System Diseases","Dermatologic Agents","INTERVENTIONAL","TREATMENT",[32],"PHASE2",{"count":34,"type":35},400,"ESTIMATED",[37],{"type":38,"name":23,"description":39,"armGroupLabels":40},"DRUG","Participants will receive IMG-007 subcutaneously.",[41],"IMG-007 Dose",[43],{"measure":44,"description":45,"timeFrame":46},"Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis","Incidence and severity of TEAEs, including treatment-emergent SAEs, AESIs, and AEs leading to discontinuation","Baseline, Week 44",[48,50,52,54,56,58,60,62,64,66],{"measure":49,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007 based on body temperature (Celsius)",{"measure":51,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007 based on pulse rate (beats per minute)",{"measure":53,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007 based on respiratory rate (breaths per minute)",{"measure":55,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007 based on blood pressure (systolic and diastolic) (mmHg)",{"measure":57,"timeFrame":46},"Number of Participants With Clinically Significant Abnormal (defined by rate, rhythm, morphology, and conduction abnormalities) ECG Findings (unit is number of participants).",{"measure":59,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007, as assessed by hematology",{"measure":61,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007, as assessed by blood chemistry",{"measure":63,"timeFrame":46},"Characterize the safety of long-term treatment with IMG-007, as assessed by urinalysis",{"measure":65,"timeFrame":46},"Evaluate the effect of long-term treatment with IMG-007 on disease activity as assessed by Eczema Area and Severity Index (EASI)",{"measure":67,"timeFrame":46},"Evaluate the effect of long-term treatment with IMG-007 on disease activity as assessed by Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)","ALL","18 Years","75 Years",false,{"inclusion":73,"exclusion":74,"raw_text":75},[],[],"Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203",[77,78],"ADULT","OLDER_ADULT",[80,89,96,104,111,119,127,132,139,147,155,163,170,178,186,194,202,211,218,226,233,240,248],{"facility":81,"city":82,"state":83,"zip":84,"country":85,"geoPoint":86},"Inmagene Site 1","Lancaster","California","93534","United States",{"lat":87,"lon":88},34.69804,-118.13674,{"facility":90,"city":91,"state":83,"zip":92,"country":85,"geoPoint":93},"Inmagene Site 23","Los Angeles","90095",{"lat":94,"lon":95},34.05223,-118.24368,{"facility":97,"city":98,"state":99,"zip":100,"country":85,"geoPoint":101},"Inmagene Site 19","Ocala","Florida","34470",{"lat":102,"lon":103},29.1872,-82.14009,{"facility":105,"city":106,"state":99,"zip":107,"country":85,"geoPoint":108},"Inmagene Site 4","Tampa","33609",{"lat":109,"lon":110},27.94752,-82.45843,{"facility":112,"city":113,"state":114,"zip":115,"country":85,"geoPoint":116},"Inmagene Site 2","Rolling Meadows","Illinois","60008",{"lat":117,"lon":118},42.08419,-88.01313,{"facility":120,"city":121,"state":122,"zip":123,"country":85,"geoPoint":124},"Inmagene Site 6","Kew Gardens","New York","11415",{"lat":125,"lon":126},40.71427,-73.83097,{"facility":128,"city":122,"state":122,"zip":129,"country":85,"geoPoint":130},"Inmagene Site 21","10029",{"lat":125,"lon":131},-74.00597,{"facility":133,"city":134,"state":122,"zip":135,"country":85,"geoPoint":136},"Inmagene Site 11","Woodbury","11797",{"lat":137,"lon":138},41.36454,-74.10598,{"facility":140,"city":141,"state":142,"zip":143,"country":85,"geoPoint":144},"Inmagene Site 20","Charlotte","North Carolina","28277",{"lat":145,"lon":146},35.22709,-80.84313,{"facility":148,"city":149,"state":150,"zip":151,"country":85,"geoPoint":152},"Inmagene Site 10","Fargo","North Dakota","58103",{"lat":153,"lon":154},46.87719,-96.7898,{"facility":156,"city":157,"state":158,"zip":159,"country":85,"geoPoint":160},"Inmagene Site 9","Columbus","Ohio","43213",{"lat":161,"lon":162},39.96118,-82.99879,{"facility":164,"city":165,"state":158,"zip":166,"country":85,"geoPoint":167},"Inmagene Site 5","Mayfield Heights","44124",{"lat":168,"lon":169},41.51922,-81.4579,{"facility":171,"city":172,"state":173,"zip":174,"country":85,"geoPoint":175},"Inmagene Site 3","Portland","Oregon","97210",{"lat":176,"lon":177},45.52345,-122.67621,{"facility":179,"city":180,"state":181,"zip":182,"country":85,"geoPoint":183},"Inmagene Site 12","Anderson","South Carolina","29621",{"lat":184,"lon":185},34.50344,-82.65013,{"facility":187,"city":188,"state":189,"zip":190,"country":85,"geoPoint":191},"Inmagene Site 8","Southlake","Texas","76092",{"lat":192,"lon":193},32.94124,-97.13418,{"facility":195,"city":196,"state":197,"zip":198,"country":85,"geoPoint":199},"Inmagene Site 7","Burien","Washington","698168",{"lat":200,"lon":201},47.47038,-122.34679,{"facility":203,"city":204,"state":205,"zip":206,"country":207,"geoPoint":208},"Inmagene Site 15","Surrey","British Columbia","V3R 6A7","Canada",{"lat":209,"lon":210},49.10635,-122.82509,{"facility":212,"city":213,"state":205,"zip":214,"country":207,"geoPoint":215},"Inmagene Site 22","Vancouver","V6H 4B1",{"lat":216,"lon":217},49.24966,-123.11934,{"facility":219,"city":220,"state":221,"zip":222,"country":207,"geoPoint":223},"Inmagene Site 17","Greater Sudbury","Ontario","P3C 1X8",{"lat":224,"lon":225},46.49,-80.99001,{"facility":227,"city":228,"state":221,"zip":229,"country":207,"geoPoint":230},"Inmagene Site 13","Mississauga","L4Y 4C5",{"lat":231,"lon":232},43.5789,-79.6583,{"facility":234,"city":235,"state":221,"zip":236,"country":207,"geoPoint":237},"Inmagene Site 18","North Bay","P1B 3Z7",{"lat":238,"lon":239},46.3168,-79.46633,{"facility":241,"city":242,"state":243,"zip":244,"country":207,"geoPoint":245},"Inmagene Site 14","Montreal","Quebec","H2X 2V1",{"lat":246,"lon":247},45.50884,-73.58781,{"facility":249,"city":250,"state":251,"zip":252,"country":207,"geoPoint":253},"Inmagene Site 16","Saskatoon","Saskatchewan","S7K 2C1",{"lat":254,"lon":255},52.13238,-106.66892,[],[],[],[],{"nct_id":4,"conditions":261,"biomarkers":262},[19],[],{"nct_id":4,"found":15,"summary":264,"prompt_version":274},{"design":265,"status":266,"heading":267,"summary":268,"follow_up":269,"word_count":270,"commitments":271,"compensation":272,"drugs_mentioned":273},"This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 400 participants.","completed","Long-term Study of IMG-007 for Moderate-to-Severe Atopic Dermatitis","This study is evaluating the long-term safety and effectiveness of a drug called IMG-007 for people with moderate-to-severe atopic dermatitis (eczema). Participants will receive IMG-007 as an injection under the skin. The main goal is to see how safe IMG-007 is over time. This study is for adults aged 18 to 75 who have already completed a previous study (IMG-007-203) and are invited to join. The study plans to enroll about 400 people, but its current status is unclear.","The primary safety endpoint is measured at Week 44.",79,"Participants will receive IMG-007 subcutaneously (under the skin). Safety will be evaluated at Baseline and Week 44.","Not stated in the trial record.",[23],"v2"]